A Phase 3 study met endpoints for Tezspire (tezepelumab) in eosinophilic esophagitis (EoE), according to reporting on the trial outcome. AstraZeneca and Amgen said the results supported the drug’s next potential indication expansion, which would add to Tezspire’s existing label footprint. If approved, Tezspire would compete in a market where Sanofi’s Dupixent is the only approved biologic therapy. The new data—already described as meeting the primary Phase 3 goals—could broaden Tezspire beyond its current use and add momentum for a blockbuster-strength franchise across chronic allergic inflammation.